Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
Date:12/10/2008

ur Phase II trial testing bavituximab and docetaxel in advanced breast cancer patients. Our anti-viral program received global attention with a publication in the leading journal Nature Medicine highlighting the broad anti-viral potential of bavituximab and other anti-PS antibodies, and we were also awarded a broad U.S. patent covering anti-viral applications of antibodies that directly target PS. These developments, following a major government contract award last quarter to study bavituximab in viral hemorrhagic fever infections, have established our PS-targeting anti-viral platform as an approach that could represent a completely new class of drugs for the treatment of life-threatening viral infections. We look forward to reporting continued progress in our anti-PS programs in the coming months, as well as providing an update on progress in our Cotara(R) clinical program."

Mr. King continued, "Our Avid manufacturing subsidiary continued to expand its client base during the quarter and increased its manufacturing capacity with the addition of an innovative single-use bioreactor system, which should allow Avid to meet the growing demand for its cell culture production services using state-of-the-art, cost-effective technology. Avid revenues recorded this quarter were lower than last year's as a result of the timing of shipments of finished product to customers, but based on product now being readied for shipping and our backlog of orders in hand, we expect robust revenue growth from Avid over the remainder of the fiscal year, with revenues in the third quarter of FY 2009 estimated at upwards of $5 million."

Mr. King concluded, "Despite the turmoil in the global financial markets, we have never been more optimistic about the potential of our lead drug candidates. The encouraging progress in our clinical programs to date and increasing scientific recognition of the promise of our innovative technology have already
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
2. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
5. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
6. Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
7. Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008
8. Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
9. Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
10. ISTA Pharmaceuticals to Participate at the RBC Capital Markets Healthcare Conference
11. Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... chemicals, which repel water and oil and are ... industrial processing. These characteristics have made the fluorochemicals ... coatings for food paper and board. , The ... to break down and accumulate in both humans ... with harmful health effects, such as cancer, increased ...
(Date:8/27/2014)... When a friend invited Misty Mozejko to join ... was the beginning of a new way of life and a ... Misty. “I knew I needed to turn my life around but ... been, Misty stuck with the program. “It was so difficult,” she ... of my comfort zone, but between the boot camp and some ...
(Date:8/27/2014)... 27, 2014 According to market research ... Servo), Power Range (Micro, Low, Medium, High), Voltage (Low ... and Geography - Global Market Trends & Forecast to ... market with an analysis and forecast of the market ... an estimated $16.64 billion in 2014 to $22.73 billion ...
(Date:8/27/2014)... 27, 2014 Humility of Mary Health ... St. Elizabeth Boardman Health Center in Boardman beginning Sept. ... Niles beginning Sept. 8. , SlimDown teaches participants to ... to food, physical activity and behavior. , Classes run ... Boardman Health Center and Mondays at St. Joe’s at ...
(Date:8/27/2014)... Ellen V. Krieger, DDS released a new video describing her ... to describe the business and industry best practices for ... of cosmetic and family dentistry experience, Dr Ellen Krieger is ... and cared for. , Dr. Krieger has practiced dentistry in ... solid reputation of offering bright, friendly service to all of ...
Breaking Medicine News(10 mins):Health News:Leading scientists call for a stop to non-essential use of fluorochemicals 2Health News:Leading scientists call for a stop to non-essential use of fluorochemicals 3Health News:Whitby Fit Body Boot Camp Releases Gift Certificate for Two-Week Complimentary Access to Fitness Boot Camp 2Health News:Whitby Fit Body Boot Camp Releases Gift Certificate for Two-Week Complimentary Access to Fitness Boot Camp 3Health News:Variable Frequency Drives Market Worth $22.73 Billion by 2019 – New Report by MarketsandMarkets 2Health News:Humility of Mary Health Partners Offers SlimDown Classes 2Health News:Ellen V. Krieger, DDS of McLean, Virginia Announces New Video Describing Industry Best Practices 2
... MYL ),today announced that in accordance with its 2.139 ... dividend of $16.25 per,share (based on the annual dividend ... share) payable on May 15, 2008, to holders of,preferred ... Mylan Inc., with operations in more than 90 countries, ...
... "Cover the Uninsured Week," an,annual campaign that ... million,Americans who live without health insurance., ... PFE ) at:, http://media.medialink.com/WebNR.aspx?story=35042 , ... graphics and,photos for free and unrestricted use ...
... /PRNewswire-FirstCall/ - SXC Health Solutions,Corp. ("SXC" or the "Company") ... indirect, wholly-owned subsidiary has accepted for payment and,exchange all ... all,outstanding shares of common stock of National Medical Health ... share price of $7.70 in cash, without,interest, and 0.217 ...
... Say McCain Health Plan Dismantles Employer-based Health Care, ... Negative Impact, WASHINGTON, April 29 Sen. ... system that covers,more than 60 percent of non-elderly ... experts responding to the announcement of his proposal,today. ...
... dropout rate, study says , , TUESDAY, April 29 (HealthDay ... those not currently injecting drugs, are most likely to ... , University of Kent and Kings College London researchers ... programs and found that 25 percent left the programs ...
... treatments, two studies suggest , , TUESDAY, April 29 (HealthDay ... of gene variants linked to bone density and the risk ... While not a predictor of individual risk for osteoporosis, this ... they noted. , "When we look at a screening of ...
Cached Medicine News:Health News:SXC Health Solutions announces completion of exchange offer for NMHC 2Health News:SXC Health Solutions announces completion of exchange offer for NMHC 3Health News:SXC Health Solutions announces completion of exchange offer for NMHC 4Health News:McCain Would Drive Up Health Care Costs for Families, While Benefiting Health Insurance Companies 2Health News:McCain Would Drive Up Health Care Costs for Families, While Benefiting Health Insurance Companies 3Health News:Youngest Drug Users Most Likely to Leave Treatment Programs 2Health News:Genes Linked to Osteoporosis Identified 2Health News:Genes Linked to Osteoporosis Identified 3
(Date:8/26/2014)... 2014  Kewaunee Scientific Corporation (Nasdaq: KEQU ... July 31, 2014. Sales for the quarter ... the first quarter last year. Net earnings for the ... compared to net earnings of $1,587,000, or $0.61 per ... year. However, both sales and earnings in the first ...
(Date:8/26/2014)... YORK , Aug. 26, 2014 /PRNewswire/ ... research report is available in its catalogue: ... Outlook to 2020 ... Gastroscopes Market Outlook to 2020 Summary ... Gastroscopes Market Outlook to 2020", provides key ...
(Date:8/26/2014)... Del. , Aug. 26, 2014 Biomedical ... it has been named to the prestigious 2014 Inc. ... are honored to be included on this prestigious list ... said Chris Jacob , Biomedical Research Laboratories, CEO. ... and further serves to validate the hard work and ...
Breaking Medicine Technology:Kewaunee Scientific Reports Results for First Quarter 2Kewaunee Scientific Reports Results for First Quarter 3Kewaunee Scientific Reports Results for First Quarter 4Kewaunee Scientific Reports Results for First Quarter 5Kewaunee Scientific Reports Results for First Quarter 6Japan Esophagoscopes & Gastroscopes Market Outlook to 2020 2Japan Esophagoscopes & Gastroscopes Market Outlook to 2020 3Japan Esophagoscopes & Gastroscopes Market Outlook to 2020 4Japan Esophagoscopes & Gastroscopes Market Outlook to 2020 5Biomedical Research Laboratories Named to Inc. 500 List of America's Fastest-Growing Companies 2
... Single PCMCIA card provides diagnostic ... Burdicks SpiroCard is on a PCMCIA ... portable package. SpiroCard card,is full-featured and ... conventional,instrument. The device interfaces to Office,Medic ...
ASAP™ Automated Biopsy System with Channel Cut™ Needle....
Incontinence Pessaries...
The Set comes with a cross reference chart that translates ring size into the correct size of other EvaCare pessaries. The Fitting Set can be disinfected in three ways: autoclaved, boiled or cold ste...
Medicine Products: